Prosight group discloses 6.8% ADC Therapeutics (ADCT) holding in 13G/A

Rhea-AI Filing Summary

ADC Therapeutics SA received an amended Schedule 13G showing that investment entities affiliated with Prosight report beneficial ownership of 8,477,338 common shares, representing 6.8% of the company’s outstanding stock. All of these shares are held with shared voting and shared dispositive power.

The ownership is spread across Prosight-managed vehicles, including Prosight Fund and Prosight Plus Fund, which directly hold common shares, and certain managed accounts. The filing is certified as a passive investment, stating the securities were not acquired to change or influence control of ADC Therapeutics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

ADC THERAPEUTICS SA

(Name of Issuer)

Common Shares

(Title of Class of Securities)

H0036K147

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. H0036K147

1

Names of Reporting Persons

Prosight Management, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,477,338.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,477,338.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,477,338.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: The figure in Item 11 is based upon 123,877,111 common shares ("Common Shares") of ADC Therapeutics SA (the "Issuer") outstanding as of October 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the U.S. Securities and Exchange Commission (the "Commission") on November 10, 2025.

SCHEDULE 13G

CUSIP No. H0036K147

1

Names of Reporting Persons

Prosight Fund, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 402,286.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 402,286.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

402,286.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.3 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The figure in Item 11 is based upon 123,877,111 shares of Common Shares outstanding as of October 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 10, 2025.

SCHEDULE 13G

CUSIP No. H0036K147

1

Names of Reporting Persons

Prosight Plus Fund, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,849,305.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,849,305.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,849,305.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.5 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The figure in Item 11 is based upon 123,877,111 shares of Common Shares outstanding as of October 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 10, 2025.

SCHEDULE 13G

CUSIP No. H0036K147

1

Names of Reporting Persons

Prosight Partners, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,477,338.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,477,338.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,477,338.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The figure in Item 11 is based upon 123,877,111 shares of Common Shares outstanding as of October 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 10, 2025.

SCHEDULE 13G

CUSIP No. H0036K147

1

Names of Reporting Persons

W. Lawrence Hawkins

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,477,338.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,477,338.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,477,338.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: The figure in Item 11 is based upon 123,877,111 shares of Common Shares outstanding as of October 31, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Commission on November 10, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ADC THERAPEUTICS SA
(b)	Address of issuer's principal executive offices: Biopole, Route de la Corniche 3B Epalinges, V8, 1066
Item 2.
(a)	Name of person filing: This statement is jointly filed by and on behalf of each of Prosight Management, LP, a Delaware limited partnership ("Prosight Management"), Prosight Fund, LP, a Delaware limited partnership ("Prosight Fund"), Prosight Plus Fund, LP, a Delaware limited partnership ("Prosight Plus Fund"), Prosight Partners, LLC, a Delaware limited liability company ("Prosight Partners"), and W. Lawrence Hawkins (collectively referred herein as "Reporting Persons"). Prosight Management is the general partner and investment manager of, and may be deemed to indirectly beneficially own securities owned by, Prosight Fund and Prosight Plus Fund. Prosight Management is a sub-advisor for certain separate managed accounts (collectively, the "Managed Accounts") and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Prosight Partners is the general partner of, and may be deemed to beneficially own, securities beneficially owned by Prosight Management. Mr. Hawkins is the sole manager of, and may be deemed to beneficially own securities beneficially owned by, Prosight Partners. Prosight Fund, Prosight Plus Fund and the Managed Accounts are the record and direct beneficial owner of the Common Shares covered by this statement. Prosight Fund disclaims beneficial ownership of the Common Shares held by the Managed Accounts and the Common Shares held by Prosight Plus Fund. Prosight Plus Fund disclaims beneficial ownership of the Common Shares held by the Managed Accounts and the Common Shares held by Prosight Fund. Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Act") or any other purpose, the beneficial owner of any securities covered by this statement. Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is c/o Prosight Management, LP, 5956 Sherry Lane, Suite 1365, Dallas, Texas 75225.
(c)	Citizenship: See Item 4 on the cover page(s) hereto.
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: H0036K147
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover pages hereto.
(b)	Percent of class: See Item 11 on the cover pages hereto.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover pages hereto.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Prosight Management, LP

Signature:	Prosight Partners, LLC
Name/Title:	General Partner
Date:	02/13/2026

Signature:	/s/ W. Lawrence Hawkins
Name/Title:	Sole Manager of the General Partner
Date:	02/13/2026

Prosight Fund, LP

Signature:	Prosight Management, LP
Name/Title:	General Partner
Date:	02/13/2026

Signature:	Prosight Partners, LLC
Name/Title:	Sole Manager of the General Partner
Date:	02/13/2026

Signature:	/s/ W. Lawrence Hawkins
Name/Title:	Sole Manager of the General Partner of the General Partner
Date:	02/13/2026

Prosight Plus Fund, LP

Signature:	Prosight Management, LP
Name/Title:	General Partner
Date:	02/13/2026

Signature:	Prosight Partners, LLC
Name/Title:	General Partner of the General Partner
Date:	02/13/2026

Signature:	/s/ W. Lawrence Hawkins
Name/Title:	Sole Manager of the General Partner of the General Partner
Date:	02/13/2026

Prosight Partners, LLC

Signature:	/s/ W. Lawrence Hawkins
Name/Title:	Sole Manager
Date:	02/13/2026

W. Lawrence Hawkins

Signature:	/s/ W. Lawrence Hawkins
Name/Title:	W. Lawrence Hawkins
Date:	02/13/2026

Exhibit Information

Exhibit 99.1: Joint Filing Agreement (incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on April 17, 2023, by the Reporting Persons with the SEC).

FAQ

What percentage of ADC Therapeutics (ADCT) shares does the Prosight group report owning?

The Prosight group reports beneficial ownership of 6.8% of ADC Therapeutics common shares. This corresponds to 8,477,338 shares, based on 123,877,111 shares outstanding as of October 31, 2025, as disclosed in the company’s Form 10-Q.

How many ADC Therapeutics (ADCT) shares does Prosight Fund directly beneficially own?

Prosight Fund directly beneficially owns 402,286 ADC Therapeutics common shares, representing 0.3% of the class. This percentage uses the company’s reported 123,877,111 outstanding common shares as of October 31, 2025, from its quarterly report on Form 10-Q.

How many ADC Therapeutics (ADCT) shares does Prosight Plus Fund report owning?

Prosight Plus Fund reports beneficial ownership of 1,849,305 ADC Therapeutics common shares, equal to 1.5% of the outstanding class. The calculation is based on 123,877,111 common shares outstanding as of October 31, 2025, per ADC Therapeutics’ Form 10-Q.

Who are the reporting persons in the ADC Therapeutics (ADCT) Schedule 13G/A amendment?

The reporting persons are Prosight Management, LP, Prosight Fund, LP, Prosight Plus Fund, LP, Prosight Partners, LLC, and W. Lawrence Hawkins. Prosight Management and Prosight Partners serve as general partners, and Hawkins is the sole manager of Prosight Partners.

Is the Prosight group’s stake in ADC Therapeutics (ADCT) reported as a passive investment?

Yes. The filing certifies that the ADC Therapeutics securities were not acquired and are not held for the purpose or effect of changing or influencing control of the issuer, and are not held in connection with any transaction having that purpose or effect.

What is the reference share count used to calculate Prosight’s ownership in ADC Therapeutics (ADCT)?

The reported ownership percentages use 123,877,111 ADC Therapeutics common shares outstanding as the reference. This figure comes from the company’s Form 10-Q for the quarter ended September 30, 2025, which stated shares outstanding as of October 31, 2025.

What type of voting and dispositive power does the Prosight group report over ADC Therapeutics (ADCT) shares?

The Prosight entities and W. Lawrence Hawkins report 0 shares with sole voting or dispositive power and 8,477,338 shares with shared voting and shared dispositive power. This means decisions to vote or dispose of these shares are made on a shared, not individual, basis.